About the job
Telix Pharmaceuticals is a dynamic and rapidly expanding radiopharmaceutical company headquartered in Australia, with additional offices in Belgium, Japan, Switzerland, and the United States. Our mission is to fulfill the promise of precision medicine through targeted radiation therapies. Our core purpose is to develop innovative products that enhance the quality of life for patients battling cancer and rare diseases. In this role, you will be instrumental in supporting the global rollout of our prostate cancer imaging agent while also contributing to the advancement of our portfolio of late clinical-stage products that address significant unmet needs in oncology and rare diseases.
Join Us at Telix
The CMC Program Lead will spearhead the CMC Sub-Team, acting as the primary point of contact for all CMC matters within the program matrix for our early-stage antibody-conjugate radiopharmaceutical diagnostic and therapeutic assets. You will be responsible for developing, executing, and maintaining an integrated CMC strategy and plan based on Quality by Design (QbD) principles, ensuring alignment with Stage-Gate requirements. This encompasses Drug Substance, Drug Product, Analytical Development, and Supply Chain from preclinical development through the end of Phase 1 (first-in-human studies). As the cross-functional integrator, you will take ownership of all CMC deliverables, fostering relationships with functional Subject Matter Experts (SMEs), internal manufacturing sites, and external partners to facilitate alignment, documentation of decisions, risk management, and Stage-Gate preparedness.
